Last reviewed · How we verify
NCT03092401: HPS
Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study
trial in Hepatopulmonary Syndrome in 142 participants. Status unknown.
31 March 2017
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 142 |
| Start date | 1 October 2015 |
| Primary completion | 31 March 2017 |
| Estimated completion | 31 March 2017 |
Conditions studied
- Hepatopulmonary Syndrome — all drugs for Hepatopulmonary Syndrome →
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Hepatopulmonary Syndrome or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatopulmonary Syndrome is a respiratory complication of liver cirrhosis defined as a triad: hypoxemia (PaO2 \< 80 mmHg in room air), chronic liver disease and intrapulmonary vasodilatations. Its prevalence varies between 4 and 32%. Numerous treatments have been tried but the only efficient therapy to cure the syndrome is liver transplantation. Without transplantation it is associated with a higher mortality which is the reason why hepatopulmonary syndrome patients have a higher priority to transplantation. However it appears in some restricted studies that hepatopulmonary syndrome is associated with more postoperative complications (infections, vascular and biliary complications, prolonged length of mechanical ventilation…). The investigators hypothesised that hepatopulmonary syndrome patients have more postoperative complications after liver transplantation than non hepatopulmonary syndrome patients matched on age, MELD (Model for End-Stage Liver Disease) score, comorbidities, perioperative transfusion and noradrenaline doses.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hepatopulmonary Syndrome and Post-Liver Transplantation Complications: A Case-Control Study.
Morvan A, Gazon M, Duperret S, Schmitt Z, et al · · 2020 · cited 2× · PMID 33335697
Verify or expand the search:
- PubMed search for NCT03092401
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03092401 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 28 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03092401.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing